Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488105 · ClinicalTrials.gov registry record · Phase 2
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
A Phase 2 study of Cardiovascular Diseases and Atherosclerosis, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT06488105 is a Phase 2 study of Cardiovascular Diseases and Atherosclerosis that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 130 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06488105, a Phase 2 study of Cardiovascular Diseases and Atherosclerosis, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
Conditions Studied
Interventions
- DRUG Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
- BEHAVIORAL Healthy Lifestyle Counseling
- OTHER Outpatient Followup
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06488105
The ClinicalTrials.gov registry entry for NCT06488105 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Statin (rosuvastatin 10 or 40 mg daily, depending on risk) is the first listed.
NCT06488105 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06488105 about?
NCT06488105 is a clinical study titled "Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial". Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency departm...
What is the current status of trial NCT06488105?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2024-08-05. Estimated completion is 2029-03-31.
What conditions does trial NCT06488105 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis, Hypercholesterolemia, Lipid Disorder.
What interventions are being tested in trial NCT06488105?
The interventions under investigation include: Statin (rosuvastatin 10 or 40 mg daily, depending on risk) (DRUG), Healthy Lifestyle Counseling (BEHAVIORAL), Outpatient Followup (OTHER).
Who is sponsoring clinical trial NCT06488105?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06488105 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.